Please login to the form below

Not currently logged in
Email:
Password:

YM BioSciences

This page shows the latest YM BioSciences news and features for those working in and with pharma, biotech and healthcare.

Baxter and CTI's Jakafi rival clears phase III trial

Baxter and CTI's Jakafi rival clears phase III trial

Other JAK2 inhibitors coming through the pipeline for myelofibrosis include Gilead Sciences' CYT387, which it acquired as part of its $510m takeover of YM Biosciences at the end of 2012.

Latest news

  • Jakafi cleared for bone marrow disorder by FDA Jakafi cleared for bone marrow disorder by FDA

    Other JAK inhibitors coming through the pipeline include Gilead Sciences' CYT387, acquired as part of its $510m takeover of YM Biosciences at the end of 2012 and Cell Therapeutics/Baxter's

  • Feverish activity

    CIMYM (a subsidiary of YM BioSciences) is developing nimotuzumab (TheraCIM h-R3, Theraloc), an EGFR antagonist with the intent of blocking epithelial growth factor and tumour growth factor from binding to ... Another media release from YM BioSciences, in

  • Battling breast cancer

    YM Biosciences' tesmilifene is a histamine antagonist in phase III trials, which has been granted fast track status by the FDA for enhancing the activity of anthracycline chemotherapy in the treatment

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics